Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation.

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after

autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

by Michele Cavo, Lucia Pantani, Maria Teresa Petrucci, Francesca Patriarca, Elena Zamagni, Daniela Donnarumma, Claudia Crippa, Mario Boccadoro, Giulia Perrone, Antonietta Falcone, Chiara Nozzoli, Renato Zambello, Luciano Masini, Anna Furlan, Annamaria Brioli, Daniele Derudas, Stelvio Ballanti, Maria Laura Dessanti, Valerio

De Stefano, Angelo Michele Carella, Magda Marcatti, Andrea Nozza, Felicetto Ferrara, Vincenzo Callea, Catello Califano, Annalisa Pezzi, Anna Baraldi, Mariella

Grasso, Pellegrino Musto, and Antonio Palumbo

BloodVolume 120(1):9-19

July 5, 2012

©2012 by American Society of Hematology

CONSORT diagram of patient flow through the study.

Michele Cavo et al. Blood 2012;120:9-19

©2012 by American Society of Hematology

Analysis of outcomes from the start of consolidation therapy with VTD or TD. Kaplan-Meier curves for TTP (A), PFS (B), and OS (C) from the landmark of starting consolidation therapy. *P

value according to log-rank test.

Michele Cavo et al. Blood 2012;120:9-19

©2012 by American Society of Hematology

Kaplan-Meier curves for PFS from the landmark of starting consolidation therapy.

Michele Cavo et al. Blood 2012;120:9-19

©2012 by American Society of Hematology

Kaplan-Meier curves for PFS from the landmark of starting consolidation therapy according to the presence or absence of cytogenetic abnormalities.

Michele Cavo et al. Blood 2012;120:9-19

©2012 by American Society of Hematology

Kaplan-Meier curves for PFS from the landmark of starting consolidation therapy according to t(4;14) positivity or negativity.

Michele Cavo et al. Blood 2012;120:9-19

©2012 by American Society of Hematology